Answers are grounded in this paper and cite their sources.
Objectives: CIMAvax-EGF is a therapeutic vaccine registered as switch maintenance therapy. This vaccine induces antibodies against self EGF that affect EGF-EGFR interaction. The aim of this study was to evaluate safety and efficacy of CIMAvax-EGF in the context of primary care.
No takes yet. Share an insight, caveat, or question.
Hernández et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: